Corcept Therapeutics announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing’s syndrome (hypercortisolism) caused by an adrenal adenoma or adrenal hyperplasia. “Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “GRADIENT is the first prospective placebo-controlled study to be conducted exclusively in these patients with Cushing’s syndrome. We expect data from GRADIENT in the fourth quarter of this year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics management to meet with Truist
- Bad News for Corcept Therapeutics Stock: This New Risk Has Been Added
- Corcept Therapeutics price target raised to $42 from $36 at Truist
- Corcept Therapeutics price target raised to $38 from $28 at H.C. Wainwright
- Corcept Therapeutics announces preliminary results from CATALYST study